PCM
BXRX

Pinz Capital Management’s Baudax Bio, Inc. Common Stock BXRX Stock Holding History

Pinz Capital Management’s Portfolio BXRX Stock Details BXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-15
Closed -$16K – 501
2021
Q2 		$16K Buy
+15
New +$19.6K ﹤0.01% 387

Other funds holding BXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Pinz Capital Management's BXRX Position: Q3 2021 in Review

Pinz Capital Management sold out of Baudax Bio, Inc. Common Stock (BXRX) in Q3 2021, closing a stake of 15 shares — an estimated $16K sold.

Pinz Capital Management first reported a position in BXRX in Q2 2021 and held it in 1 quarter. The position peaked at $16K in Q2 2021. 26 funds tracked by Wall St. Rank hold BXRX as of Q3 2021.

  • Pinz Capital Management reported no remaining Baudax Bio, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Pinz Capital Management sold 15 Baudax Bio, Inc. Common Stock shares in Q3 2021, an estimated $16K.
  • Pinz Capital Management first reported a position in Baudax Bio, Inc. Common Stock in Q2 2021 and held it in 1 quarter.
  • Pinz Capital Management's Baudax Bio, Inc. Common Stock position peaked at $16K in Q2 2021.
  • 26 funds tracked by Wall St. Rank held Baudax Bio, Inc. Common Stock as of Q3 2021.

Based on Pinz Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.